<DOC>
	<DOCNO>NCT00861679</DOCNO>
	<brief_summary>To evaluate whether HSCT match family unrelated donor ( MD ) equivalent HSCT match sibling donor ( MSD ) . To evaluate efficacy HSCT mismatch family unrelated donor ( MMD ) compare HSCT MSD/MD . To determine whether therapy carry accord main HSCT protocol recommendation . The standardisation treatment option HSCT different donor type aim achievement optimal comparison survival HSCT survival chemotherapy . To prospectively evaluate compare incidence acute chronic GvHD HSCT MSD , MD MMD .</brief_summary>
	<brief_title>Therapy Protocol Acute Lymphoblastic Leukemia Stem Cell Transplantation International</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>patient ALL ( except patient BALL ) fulfil follow criterion : age time initial diagnosis relapse diagnosis , respectively â‰¤18 year indication allogeneic HSCT complete remission ( CR ) achieve SCT write consent parent ( legal guardian ) , indicate , minor patient via `` Informed Consent Form '' pregnancy secondary malignancy previous HSCT HSCT perform study participate centre . sign inform consent parent ( legal guardian ) pregnancy secondary malignancy previous HSCT</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>HSCT</keyword>
	<keyword>ALL</keyword>
	<keyword>GvHD</keyword>
</DOC>